Subtopic Deep Dive

SWI/SNF Chromatin Remodeling Complexes in Cancer
Research Guide

What is SWI/SNF Chromatin Remodeling Complexes in Cancer?

SWI/SNF chromatin remodeling complexes are multi-subunit ATP-dependent machines that reposition nucleosomes to regulate gene expression, with frequent mutations across 20% of human cancers acting as tumor suppressors.

SWI/SNF complexes contain subunits like ARID1A, SNF5, and BRG1, whose mutations disrupt chromatin architecture in cancers including ovarian, colorectal, and medulloblastoma. The Cancer Genome Atlas Network (2012) identified SWI/SNF alterations in colon cancer (8456 citations). Shain and Pollack (2013) cataloged ubiquitous SWI/SNF mutations across cancer types (559 citations).

Curated Papers

Key Challenges

Why It Matters

SWI/SNF dysfunction drives oncogenesis by altering enhancer maintenance and lineage-specific gene expression, as shown in Alver et al. (2017) where complex loss impairs enhancer function (415 citations). In ovarian cancers, ARID1A mutations occur in preneoplastic lesions, implicating early tumor suppression loss (Wiegand et al., 2010; 1647 citations). Therapeutic targeting of residual SWI/SNF subunits or epigenetic compensation offers strategies for 20% of cancers, with Guan et al. (2011) linking ARID1A to gynecologic tumor suppression (443 citations). Roberts et al. (2002) demonstrated rapid tumorigenesis upon SNF5 inversion, highlighting preclinical models for intervention (332 citations).

Key Research Challenges

Heterogeneous Subunit Mutations

SWI/SNF mutations vary by cancer type, with ARID1A prevalent in ovarian cancers (Wiegand et al., 2010) and SNF5 in rhabdoid tumors (Roberts et al., 2002). This heterogeneity complicates universal therapeutic targeting. Shain and Pollack (2013) documented mutations across diverse cancers, requiring context-specific analysis.

Epigenetic Mechanism Elucidation

Precise mechanisms linking SWI/SNF loss to oncogene activation remain unclear despite known nucleosome repositioning roles (Hargreaves and Crabtree, 2011). Enhancer maintenance defects occur upon complex disruption (Alver et al., 2017). Functional studies demand advanced genomics integration.

Therapy Development Barriers

Restoring SWI/SNF function proves challenging due to multi-subunit complexity and synthetic lethality dependencies. Epigenetic therapies show promise in ovarian cancer models (Moufarrij et al., 2019). Clinical translation lags behind mutation prevalence data (Cancer Genome Atlas Network, 2012).

Essential Papers

Comprehensive molecular characterization of human colon and rectal cancer

The Cancer Genome Atlas Network · 2012 · Nature · 8.5K citations

<i>ARID1A</i> Mutations in Endometriosis-Associated Ovarian Carcinomas

Kimberly C. Wiegand, Sohrab P. Shah, Osama M. Al‐Agha et al. · 2010 · New England Journal of Medicine · 1.6K citations

These data implicate ARID1A as a tumor-suppressor gene frequently disrupted in ovarian clear-cell and endometrioid carcinomas. Since ARID1A mutation and loss of BAF250a can be seen in the preneopla...

ATP-dependent chromatin remodeling: genetics, genomics and mechanisms

Diana C. Hargreaves, Robert H. Crabtree · 2011 · Cell Research · 896 citations

Novel mutations target distinct subgroups of medulloblastoma

Giles Robinson, Matthew Parker, Tanya A. Kranenburg et al. · 2012 · Nature · 844 citations

Medulloblastoma is a malignant childhood brain tumour comprising four discrete subgroups. Here, to identify mutations that drive medulloblastoma, we sequenced the entire genomes of 37 tumours and m...

The Spectrum of SWI/SNF Mutations, Ubiquitous in Human Cancers

A. Hunter Shain, Jonathan R. Pollack · 2013 · PLoS ONE · 559 citations

SWI/SNF is a multi-subunit chromatin remodeling complex that uses the energy of ATP hydrolysis to reposition nucleosomes, thereby modulating gene expression. Accumulating evidence suggests that SWI...

<i>ARID1A</i> , a Factor That Promotes Formation of SWI/SNF-Mediated Chromatin Remodeling, Is a Tumor Suppressor in Gynecologic Cancers

Bin Guan, Tian‐Li Wang, Ie‐Ming Shih · 2011 · Cancer Research · 443 citations

Abstract ARID1A (BAF250A) promotes the formation of SWI/SNF chromatin remodeling complexes containing BRG1 or BRM. It has emerged as a candidate tumor suppressor based on its frequent mutations in ...

The SWI/SNF chromatin remodelling complex is required for maintenance of lineage specific enhancers

B. Alver, Kimberly H. Kim, Ping Lu et al. · 2017 · Nature Communications · 415 citations

Reading Guide

Foundational Papers

Start with Cancer Genome Atlas Network (2012) for broad mutation landscape (8456 citations), Wiegand et al. (2010) for ARID1A in ovarian cancer (1647 citations), and Shain and Pollack (2013) for pan-cancer spectrum (559 citations) to establish prevalence and tumor suppressor evidence.

Recent Advances

Study Alver et al. (2017) for enhancer maintenance mechanisms (415 citations) and Moufarrij et al. (2019) for epigenetic therapy applications in ovarian cancer.

Core Methods

Core techniques include whole-genome sequencing (Robinson et al., 2012), conditional mouse models (Roberts et al., 2002), and genomics for nucleosome positioning (Hargreaves and Crabtree, 2011).

How PapersFlow Helps You Research SWI/SNF Chromatin Remodeling Complexes in Cancer

Discover & Search

Research Agent uses searchPapers('SWI/SNF mutations cancer') to retrieve 250M+ OpenAlex papers, including Wiegand et al. (2010), then citationGraph to map influence across ovarian and colorectal cancers. findSimilarPapers on Shain and Pollack (2013) uncovers related medulloblastoma studies like Robinson et al. (2012). exaSearch drills into ARID1A-specific preneoplastic lesion data.

Analyze & Verify

Analysis Agent applies readPaperContent to extract mutation frequencies from Cancer Genome Atlas Network (2012), then runPythonAnalysis with pandas to quantify SWI/SNF alteration rates across TCGA cohorts. verifyResponse via CoVe chain-of-verification cross-checks claims against Hargreaves and Crabtree (2011), with GRADE grading for evidence strength on tumor suppressor roles. Statistical verification confirms 20% prevalence from raw genomic data.

Synthesize & Write

Synthesis Agent detects gaps in ARID1A therapy post-mutation via contradiction flagging across Guan et al. (2011) and Moufarrij et al. (2019). Writing Agent uses latexEditText for manuscript sections, latexSyncCitations to integrate Roberts et al. (2002), and latexCompile for figure-ready output. exportMermaid generates chromatin remodeling pathway diagrams from Alver et al. (2017).

Use Cases

"Analyze mutation frequencies of SWI/SNF subunits in TCGA colorectal cancer data"

Research Agent → searchPapers('SWI/SNF TCGA colorectal') → Analysis Agent → readPaperContent(Cancer Genome Atlas Network 2012) → runPythonAnalysis(pandas aggregation of mutation rates) → CSV table of ARID1A/SNF5 prevalences with p-values.

"Draft LaTeX review section on ARID1A loss in ovarian cancer progression"

Synthesis Agent → gap detection(Wiegand et al. 2010 + Guan et al. 2011) → Writing Agent → latexEditText(structured paragraph) → latexSyncCitations(10 refs) → latexCompile(PDF with inline citations and figure from preneoplastic data).

"Find GitHub repos analyzing SWI/SNF chromatin data from recent papers"

Research Agent → searchPapers('SWI/SNF enhancer analysis') → Code Discovery → paperExtractUrls(Alver et al. 2017) → paperFindGithubRepo → githubRepoInspect(NGS chromatin tracks) → runnable Jupyter notebook for nucleosome positioning stats.

Automated Workflows

Deep Research workflow conducts systematic review: searchPapers('SWI/SNF cancer mutations') → citationGraph → DeepScan(7-step: read 50+ papers like Robinson et al. 2012 → verifyResponse) → structured report on subtype-specific alterations. Theorizer generates hypotheses on synthetic lethality: input Shain and Pollack (2013) + Roberts et al. (2002) → theory on BRG1 compensation. DeepScan verifies enhancer claims from Alver et al. (2017) with CoVe checkpoints.

Try Doxa for SWI/SNF Chromatin Remodeling Complexes in Cancer Research

Frequently Asked Questions

What defines SWI/SNF complexes in cancer research?

SWI/SNF are ATP-dependent chromatin remodelers with subunits like ARID1A and SNF5 frequently mutated in 20% of cancers, functioning as tumor suppressors (Shain and Pollack, 2013).

What methods identify SWI/SNF mutations?

Whole-genome sequencing detects mutations, as in medulloblastoma (Robinson et al., 2012) and TCGA colorectal analysis (Cancer Genome Atlas Network, 2012); immunohistochemistry confirms protein loss like BAF250a in ovarian tumors (Wiegand et al., 2010).

What are key papers on SWI/SNF in cancer?

Foundational works include Wiegand et al. (2010; ARID1A in ovarian, 1647 citations), Cancer Genome Atlas Network (2012; colorectal, 8456 citations), and Shain and Pollack (2013; spectrum across cancers, 559 citations).

What open problems exist in SWI/SNF cancer research?

Challenges include targeting heterogeneous mutations, elucidating enhancer-specific roles (Alver et al., 2017), and developing therapies beyond epigenetic drugs (Moufarrij et al., 2019).